

KURZPROTOKOLL
Checkmate CA209-817

| | |
|--|---|
| Öffentlicher Titel | Nivolumab und Ipilimumab bei fortgeschrittenem Nicht-kleinzelligem Lungenkrebs |
| Wissenschaftl. Titel | A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants With Advanced Malignancies. |
| Kurztitel | Checkmate CA209-817 |
| Studienart | multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig |
| Studienphase | Phase III/IV |
| Erkrankung | Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Zweitlinie oder höher Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Erstlinie |
| Einschlusskriterien | <ul style="list-style-type: none">- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)- No prior systemic anticancer therapy (including EGFR and ALK inhibitors)- Tissue or Programmed death-ligand 1 (PD-L1) results available |
| Ausschlusskriterien | <ul style="list-style-type: none">- Untreated brain metastases- An active malignancy that requires concurrent intervention- Active, known or suspected autoimmune disease- Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer |
| Alter | 18 Jahre und älter |
| Prüfzentren | Krankenhaus Nordwest GmbH (Rekrutierung beendet) Klinik für Onkologie und Hämatologie Steinbacher Hohl 2-26 60488 Frankfurt am Main Manuela Padberg Tel: 069 7601-4558 Fax: 069 7601-3655 padberg.manuela@khnw.de |
| Sponsor | Bristol-Myers Squibb |
| Registrierung in anderen Studienregistern | ClinicalTrials.gov NCT02869789 EudraCT 2016-002621-10 |